Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : pNGVL3-hICD,Pembrolizumab,rhuGM-CSF
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Timefolio Asset
Deal Size : $22.7 million
Deal Type : Series C Financing
Aston Sci. Raises USD 22.7 Million Series C Funding
Details : The raised fund will be used in global clinical development and drug discovery projects. Starting with the phase 2 randomized-controlled clinical trial for AST-301 expected to take place during the second quarter of this year, the value of pipeline will ...
Product Name : AST-301
Product Type : Vaccine
Upfront Cash : Undisclosed
March 03, 2022
Lead Product(s) : pNGVL3-hICD,Pembrolizumab,rhuGM-CSF
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Timefolio Asset
Deal Size : $22.7 million
Deal Type : Series C Financing
Lead Product(s) : pNGVL3-hICD,Pembrolizumab,rhuGM-CSF
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Phase 2 clinical trial of AST-301 (pNGVL3-hICD) adopt placebo-controlled randomized design and clinical trial in which AST-301 is administered in combination with standard treatments, in patients with high risk of recurrence following curative surgery.
Product Name : AST-301
Product Type : Vaccine
Upfront Cash : Inapplicable
February 09, 2022
Lead Product(s) : pNGVL3-hICD,Pembrolizumab,rhuGM-CSF
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
